follicular lymphoma
FDA Approves Monjuvi for Relapsed or Refractory Follicular Lymphoma
The FDA approved tafasitamab (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or ...
JUNE 20, 2025
Addition of Second Monoclonal Antibody Improves Outcomes of Follicular Lymphoma
When tafasitamab (Monjuvi, Incyte), an anti-CD19 monoclonal antibody, is added to a regimen that includes the ...
DECEMBER 18, 2024
FDA Grants Accelerated Approval to Epkinly for Relapsed or Refractory Follicular Lymphoma
The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab U.S.), a bispecific CD20-directed CD3 ...
JUNE 27, 2024
FDA Grants Accelerated Approval to Breyanzi for Follicular Lymphoma
The FDA has granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics) for adults with ...
MAY 17, 2024
FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for ...
MARCH 8, 2024
FDA Approves Tisagenlecleucel for Relapsed or Refractory FL
The FDA has granted accelerated approval for tisagenlecleucel (Kymriah, Novartis) for the treatment of adult ...
JUNE 3, 2022
FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma
The FDA has approved axicabtagene ciloleucel (Kite Pharma) for the treatment of adults with relapsed or refractory ...
MARCH 9, 2021
FDA Grants Accelerated Approval to Ukoniq for Previously Treated MZL and FL
The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma ...
FEBRUARY 17, 2021
Tazverik Approved to Treat Some Patients With Follicular Lymphoma
The FDA granted accelerated approval to tazemetostat (Tazverik, Epizyme) to treat adults with relapsed or ...
JUNE 22, 2020
Novel Agent Found Effective in B-Cell Cancers, Even After CAR T-Cell Failure
A novel investigational bispecific antibody therapy called mosunetuzumab produced durable complete response sin ...
FEBRUARY 24, 2020
Revlimid-Rituximab Combo Approved for FL and MZL
The FDA approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product for previously treated ...
JUNE 4, 2019
FDA Approves Gazyva for Previously Untreated Advanced FL
The FDA granted regular approval to obinutuzumab (Gazyva, Genentech) for use in treatment-naive adults with stage ...
NOVEMBER 21, 2017
